Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target

Benzinga Newsdesk www.benzinga.com Negative 55.5%

Neg 55.5% Neu 0% Pos 0%

Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and maintains $7 price target.

Comments

No comments yet. Be the first!